For everyone who has ever sat in a DFU clinic and wondered how on earth do we get from biomarker discovery to a tool I can use at the chairside in this patient’s lifetime?—our friends at the NIDDK Diabetic Foot Consortium (DFC) have just published the methodological scaffolding that may answer that question.
In a new paper in Advances in Wound Care, Schmidt BM, Spino C, Jones TLZ, Conte M, Gordillo G, Gurtner G, Holmes C, Martin C, Maturo F, Noll K, Thelen-Perry S, Mirzadjahromi N, Sen CK, and Pop-Busui R—on behalf of the entire NIDDK DFC—describe a platform study designed for DFU biomarker validation. To our knowledge, this is the first time this trial architecture has been deployed to validate biomarkers rather than to test therapies.
What is a platform study?
A platform study uses a master protocol to evaluate multiple candidate interventions—or in this case, multiple biomarkers—simultaneously and perpetually under one piece of shared infrastructure. The design came of age in oncology, was rapidly repurposed during COVID-19 vaccine development, and has now arrived in wound healing. The economies of scale relative to running each candidate as its own discrete trial are substantial: less time, less money, fewer participants asked to start from zero.
The DFC’s twist
The DFC team has applied this design to biomarker validation, not to therapy. Under the deeply DFC-coded mantra “No DFU Goes Unstudied,” they built a flexible master protocol that enrolls a broad and inclusive spectrum of people with DFUs across the DFC clinical sites, concurrently evaluates multiple candidate biomarkers, collects 52 weeks of longitudinal data on clinical characteristics, patient-reported outcomes and standard-of-care practices, and warehouses the biospecimens and infrastructure for the next wave of biomarkers as they emerge.
That last point is the quiet star of the show. The platform is perpetual. New biomarkers can be plugged in as they mature. New therapies can plug into the same scaffolding once the predictive biomarkers are in hand.
Why it matters
The bottleneck in diabetic foot wound healing has rarely been a shortage of plausible biomarkers. The bottleneck has been the absence of standardized, multi-site, pragmatic, perpetual infrastructure to validate them at the speed the field needs. With this platform up and running, the next candidate can be evaluated in months rather than years. The next interventional trial can sit on top of clinical, biospecimen and PRO data already in flight rather than starting cold. The runway, in other words, is now built.
This is the kind of work that does not make headlines today. It is precisely the work that will turn headlines into clinical care a decade from now.
To Brian, Rodica, Chandan, Geoff, Mike, Cathie, Teresa, Gayle, Crystal, Cathy, Fleur, Kourtney, Steven, Nazila and the entire DFC team—thank you for building the runway. The rest of the field will be using it for years.
Paper: https://doi.org/10.1177/21621918251405881 · PMID 42140887 · The Consortium: diabeticfootconsortium.org
#DiabeticFoot #DFU #DFC #DiabeticFootConsortium #Biomarkers #PlatformStudy #MasterProtocol #ClinicalTrials #WoundHealing #NIDDK #LimbPreservation #NoDFUGoesUnstudied
Leave a Reply